0001564590-19-017959.txt : 20190509 0001564590-19-017959.hdr.sgml : 20190509 20190509160518 ACCESSION NUMBER: 0001564590-19-017959 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 19810465 BUSINESS ADDRESS: STREET 1: 4 CROMWELL CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 4 CROMWELL CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 biol-8k_20190509.htm 8-K biol-8k_20190509.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of report (Date of earliest event reported)

May 9, 2019

 

BIOLASE, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 

 

 

 

 

Delaware

 

001-36385

 

87-0442441

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

4 Cromwell

Irvine, California 92618

(Address of principal executive offices, including zip code)

(949) 361-1200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

BIOL

The NASDAQ Stock Market LLC

(NASDAQ Capital Market)

 


Item 2.02. Results of Operations and Financial Condition.

On May 9, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

d) Exhibits.

The following exhibit is being furnished as part of this Current Report on Form 8-K:

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release of BIOLASE, Inc., dated May 9, 2019

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BIOLASE, INC.

  

 

 

 

 

Date: May 9, 2019

 

By

 

/s/ John R. Beaver 

 

 

 

 

Name: John R. Beaver

 

 

 

 

Title: Executive Vice President and Chief Financial Officer

 

EX-99..1 2 biol-ex991_10.htm EX-99..1 biol-ex991_10.htm

 

Exhibit 99.1

 

BIOLASE Reports First Quarter 2019 Results

First Quarter U.S. Laser Revenue Increased 18% Year-Over-Year

First Quarter Operating Loss Decreased 16% Year-Over-Year

IRVINE, Calif., May 9, 2019 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.3 million for the first quarter ended March 31, 2019, an increase of 3% compared to the first quarter of 2018.

First Quarter Highlights

 

U.S. laser revenue increased 18% year over year

 

U.S. consumables and other revenue increased 4% year over year

 

Model market laser revenue, which includes Southern California and Dallas/Ft. Worth, increased 88% year over year

 

New customer growth, reduced expenses and a favorable change in product mix led to gross margin expansion of almost 400 basis points

 

Operating expenses decreased 4% year over year

 

“Our improved results for the first quarter reflect the success of our revenue growth and cost savings initiatives, including continued solid execution of our new commercial marketing efforts to increase awareness and expand adoption of our all tissue Waterlase laser,” said Todd Norbe, President and Chief Executive Officer. “We are pleased with the strong success of our two model market campaigns, and we continued to add new customers and increase utilization of our product during the quarter, driving our recurring, higher margin consumables revenue and further improving our gross margin. With this positive momentum and our focus on continued success of our go-to-market initiatives and operational improvements, we continue to feel confident in achieving our goal of becoming EBITDA positive in the fourth quarter of 2019.”

2019 First Quarter Financial Results

Net revenue for the first quarter of 2019 was $10.3 million, an increase of 3%, compared to net revenue of $10.0 million for first quarter of 2018. Excluding the non-core imaging business, revenue for the first quarter of 2019 increased 4% to $9.8 million from $9.4 million for the first quarter of 2018. U.S. laser revenue was $2.6 million for the first quarter of 2019, an 18% increase compared to U.S. laser revenue of $2.2 million for the first quarter of 2018. U.S. consumables and other revenue for the first quarter of 2019, which consists of revenue from consumable products such as disposable tips, increased 4% compared to the first quarter of 2018. Outside the U.S., laser revenue declined 4% to $3.4 million for the first quarter of 2019 compared to $3.5 million for the first quarter of 2018, whereas consumables and other revenue increased 4% year over year.


Gross margin for the first quarter of 2019 was 34%, compared to 30% for first quarter of 2018. The higher gross margin reflects new customer growth, reduced expenses and a favorable change in product mix with an increase in laser sales, which have a higher margin than the Company’s other product offerings, including its non-core imaging products which are being phased out from the Company’s product offering in the second quarter of 2019. Total operating expenses were $7.9 million for the first quarter of 2019 compared to $8.2 million for the first quarter of 2018, a decrease of over 4%. Operating loss for the first quarter of 2019, was $4.4 million, compared to an operating loss of $5.2 million in the first quarter of 2018, a decrease of 16% year over year. Net loss for the first quarter of 2019 was $4.9 million, or $0.23 per share, compared to a net loss of $5.0 million, or $0.25 per share for the first quarter of 2018.

Cash, cash equivalents, and restricted cash totaled $3.3 million as of March 31, 2019.

Subsequent to the end of the first quarter, on May 7, 2019 the Company amended its credit agreement with SWK Funding LLC to increase the total commitment in its term loan from $12.5 million to $15.0 million and to revise certain of the financial covenants. Further details of the amendment will be included in the Company’s Form 10-Q filing for the period ended March 31, 2019 to be filed with the SEC.

Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Non-GAAP Net Loss table at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's non-GAAP net loss and net loss per share.

The non-GAAP net loss for the first quarter of 2019 was $3.2 million, or $0.15 per share compared with a non-GAAP net loss of $4.0 million, or $0.20 per share for the first quarter of 2018.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the first quarter ended March 31, 2019, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 877-407-4019. For international participants outside the U.S./Canada, the dial-in number is 201-689-8337. For all callers, refer to the Conference ID 13687240. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including three-dimensional CAD/CAM intra-oral scanners and digital dentistry software. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 255 patented and 73 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 39,600 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer markets.


For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the Company’s efforts to achieve its goal of becoming EBITDA positive. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "should," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the "Risk Factors" section of BIOLASE's annual and quarterly reports filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

BIOLASE, Inc.

John R. Beaver, Executive Vice President and Chief Financial Officer

833-BIOLASE

jbeaver@biolase.com

or

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

Tables to Follow


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2019

 

 

2018

 

Products and services revenue

 

$

 

10,323

 

 

$

 

10,017

 

License fees and royalty revenue

 

 

 

3

 

 

 

 

3

 

Net revenue

 

 

 

10,326

 

 

 

 

10,020

 

Cost of revenue

 

 

 

6,804

 

 

 

 

6,987

 

Gross profit

 

 

 

3,522

 

 

 

 

3,033

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

 

3,879

 

 

 

 

3,891

 

General and administrative

 

 

 

2,393

 

 

 

 

3,037

 

Engineering and development

 

 

 

1,424

 

 

 

 

1,289

 

Change in fair value of patent litigation settlement liability

 

 

 

190

 

 

 

 

 

Total operating expenses

 

 

 

7,886

 

 

 

 

8,217

 

Loss from operations

 

 

 

(4,364

)

 

 

 

(5,184

)

Loss (gain) on foreign currency transactions

 

 

 

43

 

 

 

 

(207

)

Interest expense, net

 

 

 

478

 

 

 

 

12

 

Non-operating loss (income), net

 

 

 

521

 

 

 

 

(195

)

Loss before income tax provision

 

 

 

(4,885

)

 

 

 

(4,989

)

Income tax provision

 

 

 

15

 

 

 

 

32

 

Net loss

 

$

 

(4,900

)

 

$

 

(5,021

)

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

$

 

(0.23

)

 

$

 

(0.25

)

Diluted

 

$

 

(0.23

)

 

$

 

(0.25

)

Shares used in the calculation of net loss per share:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

21,134

 

 

 

 

20,469

 

Diluted

 

 

 

21,134

 

 

 

 

20,469

 

 


 

BIOLASE, INC.

 

CONSOLIDATED BALANCE SHEETS

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

 

(Unaudited)

 

 

(Audited)

 

ASSETS

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

2,956

 

 

$

 

8,044

 

Restricted cash

 

 

 

312

 

 

 

 

312

 

Accounts receivable, less allowance of $869 and $850 in 2019 and

   2018, respectively

 

 

 

11,743

 

 

 

 

11,112

 

Inventory

 

 

 

12,023

 

 

 

 

12,248

 

Prepaid expenses and other current assets

 

 

 

1,815

 

 

 

 

1,591

 

Total current assets

 

 

 

28,849

 

 

 

 

33,307

 

Property, plant and equipment, net

 

 

 

1,733

 

 

 

 

1,975

 

Goodwill

 

 

 

2,926

 

 

 

 

2,926

 

Other assets

 

 

 

302

 

 

 

 

308

 

Total assets

 

$

 

33,810

 

 

$

 

38,516

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

5,894

 

 

$

 

5,953

 

Accrued liabilities

 

 

 

6,713

 

 

 

 

7,538

 

Deferred revenue

 

 

 

2,513

 

 

 

 

2,476

 

Total current liabilities

 

 

 

15,120

 

 

 

 

15,967

 

Deferred income taxes, net

 

 

 

72

 

 

 

 

77

 

Warranty accrual

 

 

 

577

 

 

 

 

447

 

Other liabilities

 

 

 

162

 

 

 

 

100

 

Term loan

 

 

 

10,906

 

 

 

 

10,836

 

Total liabilities

 

 

 

26,837

 

 

 

 

27,427

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

Preferred stock, par value $0.001 per share

 

 

 

 

 

 

 

 

Common stock, par value $0.001 per share

 

 

 

21

 

 

 

 

21

 

Additional paid-in capital

 

 

 

229,269

 

 

 

 

228,430

 

Accumulated other comprehensive loss

 

 

 

(725

)

 

 

 

(670

)

Accumulated deficit

 

 

 

(221,592

)

 

 

 

(216,692

)

Total stockholders’ equity

 

 

 

6,973

 

 

 

 

11,089

 

Total liabilities and stockholders’ equity

 

$

 

33,810

 

 

$

 

38,516

 

 


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited, in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2019

 

 

2018

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(4,900

)

 

$

(5,021

)

Adjustments to reconcile net loss to net cash and cash equivalents

   used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

258

 

 

 

264

 

Provision for bad debts, net

 

 

19

 

 

 

200

 

Provision for sales allowance

 

 

 

 

 

4

 

Amortization of debt discounts

 

 

38

 

 

 

 

Amortization of debt issuance costs

 

 

49

 

 

 

7

 

Stock-based compensation

 

 

757

 

 

 

701

 

Deferred income taxes

 

 

(5

)

 

 

2

 

Earned interest income, net

 

 

(1

)

 

 

(1

)

Change in fair value of patent litigation settlement liability

 

 

190

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(650

)

 

 

186

 

Inventory

 

 

225

 

 

 

(1,103

)

Prepaid expenses and other current assets

 

 

463

 

 

 

(20

)

Accounts payable and accrued liabilities

 

 

(1,514

)

 

 

460

 

Deferred revenue

 

 

37

 

 

 

(441

)

Net cash and cash equivalents used in operating activities

 

 

(5,034

)

 

 

(4,762

)

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(8

)

 

 

(102

)

Net cash and cash equivalents used in investing activities

 

 

(8

)

 

 

(102

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Principal payments under capital lease obligation

 

 

 

 

 

(46

)

Borrowings under lines of credit

 

 

 

 

 

1,823

 

Payments of debt issuance costs

 

 

 

 

 

(74

)

Payments of equity offering costs

 

 

 

 

 

(81

)

Proceeds from exercise of stock options

 

 

3

 

 

 

2

 

Net cash and cash equivalents provided by financing activities

 

 

3

 

 

 

1,624

 

Effect of exchange rate changes

 

 

(49

)

 

 

74

 

Decrease in cash, cash equivalents and restricted cash

 

 

(5,088

)

 

 

(3,166

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

8,356

 

 

 

11,896

 

Cash, cash equivalents and restricted cash, end of period

 

$

3,268

 

 

$

8,730

 

Supplemental cash flow disclosure:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

430

 

 

$

 

Cash paid for income taxes

 

$

31

 

 

$

24

 

Cash paid for operating leases

 

$

189

 

 

$

 

Non-cash accrual for capital expenditures

 

$

24

 

 

$

4

 

Non-cash right-of-use assets obtained in exchange for lease

   obligation

 

$

824

 

 

$

 

 


Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents

Non-GAAP net loss is defined as net loss before interest, taxes, depreciation and amortization, and stock-based compensation. Management uses non-GAAP net loss in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

 

 

BIOLASE, INC.

 

Reconciliation of GAAP Net Loss to Non-GAAP Net Loss

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

 

2019

 

 

2018

 

GAAP net loss attributable to common stockholders

$

 

(4,900

)

 

$

 

(5,021

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

GAAP net loss

$

 

(4,900

)

 

$

 

(5,021

)

Adjustments:

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

478

 

 

 

 

12

 

Income tax provision

 

 

15

 

 

 

 

32

 

Depreciation and amortization

 

 

258

 

 

 

 

264

 

Change in fair value of patent litigation settlement liability

 

 

190

 

 

 

 

 

Stock-based compensation

 

 

757

 

 

 

 

701

 

Non-GAAP net loss

$

 

(3,202

)

 

$

 

(4,012

)

 

 

 

 

 

 

 

 

 

 

GAAP net loss attributable to common stockholders

   per share, basic and diluted

$

 

(0.23

)

 

$

 

(0.25

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

GAAP net loss per share, basic and diluted

$

 

(0.23

)

 

$

 

(0.25

)

Adjustments:

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

0.02

 

 

 

 

 

Income tax provision

 

 

 

 

 

 

 

Depreciation and amortization

 

 

0.01

 

 

 

 

0.01

 

Change in fair value of patent litigation settlement liability

 

 

0.01

 

 

 

 

 

Stock-based compensation

 

 

0.04

 

 

 

 

0.04

 

Non-GAAP net loss per share, basic and diluted

$

 

(0.15

)

 

$

 

(0.20

)


BIOLASE, INC.

 

GAAP Net Revenue Less Imaging Systems

 

(Unaudited, in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

 

2019

 

 

2018

 

Net revenue

$

 

10,326

 

 

$

 

10,020

 

Imaging systems revenue

 

 

(552

)

 

 

 

(583

)

Net revenue excluding imaging systems

$

 

9,774

 

 

$

 

9,437

 

 

GRAPHIC 3 gtxudfizxaai000001.jpg GRAPHIC begin 644 gtxudfizxaai000001.jpg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end